ID
38786
Beschreibung
Study ID: 108062 Clinical Study ID: 108062 Study Title: A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoietin receptor agonist, in previously treated pediatric patients with chronic idiopathic thrombocytopenic purpura (ITP). Eltrombopag PETIT: Eltrombopag in PEdiatric patients with Thrombocytopenia from ITP Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00908037 https://clinicaltrials.gov/ct2/show/NCT00908037 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: eltrombopag, Placebo Trade Name: N/A Study Indication: Purpura, Thrombocytopaenic, Idiopathic The study consists of a screening, Day 1 and three parts. All subjects were supposed to receive 24 weeks (6 months) of eltrombopag treatment during Part 2/3. Screening period: Up to 28 days prior to Day 1 of treatment. Day 1 Part 1 (Dose Finding Phase): A 24-week (6 months) open label treatment period for 5 subjects in each age cohort. (short: P1W1-P1W7, P1W8-23, P1W24/EW). A safety, PK and platelet count review took place after 12 weeks (3 months) of treatment. Subjects in the Dose Finding Phase did not participate in the Randomized Period. Part 2 (Randomized Period): A 7-week randomized, double-blind, placebo-controlled period involving 18 subjects per cohort (short: P2W1-P2W7). Part 3: An open-label treatment period where subjects randomized to eltrombopag in Part 2 received an additional 17 weeks of eltrombopag in Part 3 and subjects randomized to placebo in Part 2 received 24 weeks of eltrombopag in Part 3 (short: P3W8-P3W23, P3W24/EW, P3W8-30, P3W31/EW). Follow-up: 4 weeks following the last dose of eltrombopag (short: FUW1- FUW4). Additional ocular examinations were performed at 12 and 24 weeks (3 and 6 months) after the last dose of eltrombopag (short: FUM3, FUM6). The subjects were enrolled in 3 cohorts: Cohort 1: Subjects between 12 and 17 years old (<18 years of age at Day 1). Cohort 2: Subjects between 6 and 11 years old (<12 years of age at Day 1). Cohort 3: Subjects between 1 and 5 years old (<6 years of age at Day 1). The enrollment was started with the oldest cohort (Cohort 1). The younger cohorts were not enrolled until safety, PK and platelet counts had been reviewed in the older cohort(s). This document contains the End of treatment/Early withdrawal assessmentsand unscheduled visit assessments form.
Link
https://clinicaltrials.gov/ct2/show/NCT00908037
Stichworte
Versionen (2)
- 04.11.19 04.11.19 -
- 05.12.19 05.12.19 - Sarah Riepenhausen
Rechteinhaber
GlaxoSmithKline
Hochgeladen am
4. November 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Effects of eltrombopag in children with chronic idiopathic thrombocytopenic purpura, NCT00908037
End of treatment/Early withdrawal assessments,Unscheduled visit assessments
Beschreibung
Early withdrawal assessment check questions
Alias
- UMLS CUI-1
- C2349954
Beschreibung
Haematology lab samples
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0022885
- UMLS CUI [1,2]
- C0018941
Beschreibung
Chemistry lab samples
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0008000
- UMLS CUI [1,2]
- C0005834
Beschreibung
Blood smear
Datentyp
text
Alias
- UMLS CUI [1]
- C2238079
Beschreibung
Calculation of coagulation parameters
Datentyp
text
Alias
- UMLS CUI [1,1]
- C1441506
- UMLS CUI [1,2]
- C0005789
Beschreibung
Renal assessments
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0232804
- UMLS CUI [1,2]
- C0022885
Beschreibung
PK sample
Datentyp
text
Alias
- UMLS CUI [1,1]
- C1277698
- UMLS CUI [1,2]
- C0031328
Beschreibung
Vital signs
Datentyp
text
Alias
- UMLS CUI [1]
- C0518766
Beschreibung
If you tick yes, please check which examination has been done in the following item.
Datentyp
text
Alias
- UMLS CUI [1]
- C0200149
Beschreibung
Ophthalmic exams type
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0332307
- UMLS CUI [1,2]
- C0200149
Beschreibung
Assessment of WHO bleeding scale
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0043237
- UMLS CUI [1,2]
- C3251812
- UMLS CUI [1,3]
- C0681889
Beschreibung
If you tick yes, please note if the subject is less than 6 years of age in the following item.
Datentyp
text
Alias
- UMLS CUI [1]
- C0034380
Beschreibung
Age
Datentyp
text
Alias
- UMLS CUI [1]
- C0001779
Beschreibung
Investigational product discontinuation
Alias
- UMLS CUI-1
- C0304229
- UMLS CUI-2
- C0457454
Beschreibung
If you tick yes, please complete the primary reason in the following item. Only to fill in for End of treatmen/early withdrawal.
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C0457454
- UMLS CUI [1,3]
- C0332152
- UMLS CUI [1,4]
- C0444930
- UMLS CUI [1,5]
- C2347804
Beschreibung
If you tick "Adverse event": Record details on the Non-Serious Adverse Events or Serious Adverse Events forms as appropriate. Additionally check if the adverse event is a matter of pregnancy or if there is no subreason in the appropriate item. Select "Investigator discretion" or "Decision by subject or proxy" if none of the other primary reasons are appropriate. If you do so, please specify in the appropriate items.
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0205225
- UMLS CUI [1,2]
- C0566251
- UMLS CUI [1,3]
- C0444930
- UMLS CUI [1,4]
- C0304229
Beschreibung
Adverse event, subreason
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0392360
Beschreibung
Investigator discretion, specification
Datentyp
text
Alias
- UMLS CUI [1,1]
- C2348235
- UMLS CUI [1,2]
- C0008961
- UMLS CUI [1,3]
- C0022423
Beschreibung
Decision by subject or proxy, specification
Datentyp
text
Alias
- UMLS CUI [1,1]
- C2348235
- UMLS CUI [1,2]
- C0422727
- UMLS CUI [1,3]
- C0679006
- UMLS CUI [2,1]
- C2348235
- UMLS CUI [2,2]
- C0422727
- UMLS CUI [2,3]
- C0600420
- UMLS CUI [2,4]
- C0679006
Ähnliche Modelle
End of treatment/Early withdrawal assessments,Unscheduled visit assessments
C0018941 (UMLS CUI [1,2])
C0005834 (UMLS CUI [1,2])
C0005789 (UMLS CUI [1,2])
C0022885 (UMLS CUI [1,2])
C0200149 (UMLS CUI [1,2])
C3251812 (UMLS CUI [1,2])
C0681889 (UMLS CUI [1,3])
C0457454 (UMLS CUI-2)
C0457454 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C0444930 (UMLS CUI [1,4])
C2347804 (UMLS CUI [1,5])
C0566251 (UMLS CUI [1,2])
C0444930 (UMLS CUI [1,3])
C0304229 (UMLS CUI [1,4])
C0392360 (UMLS CUI [1,2])
C0008961 (UMLS CUI [1,2])
C0022423 (UMLS CUI [1,3])
C0422727 (UMLS CUI [1,2])
C0679006 (UMLS CUI [1,3])
C2348235 (UMLS CUI [2,1])
C0422727 (UMLS CUI [2,2])
C0600420 (UMLS CUI [2,3])
C0679006 (UMLS CUI [2,4])